This evolution culminated in the 2021 KDIGO guidelines, which formally state that a kidney biopsy is not required to diagnose MN in patients with nephrotic syndrome and a positive anti-PLA2R antibody test [59, 60]. This evidence concerns the gene PLA2R1 and nephrotic syndrome.